Corvus Pharmaceuticals CRVS Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's operating lease right-of-use assets in other assets?
- Corvus Pharmaceuticals (CRVS) reported operating lease right-of-use assets in other assets of $751K in Q1 2026.
- How has Corvus Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Corvus Pharmaceuticals's operating lease right-of-use assets in other assets decreased by 31.4% year-over-year, from $1.1M to $751K.
- What is the long-term trend for Corvus Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a -12.6% compound annual growth rate (CAGR), from $1.65M to $839K.